Novartis to buy GSK portfiolio of 22 new drugs

(AGI) Milan, June 16 - Over 25 new molecules are beingdeveloped to treat 10 neoplasia conditions. In fact, there willbe 22 new drugs to treat patients with cancer or haematologicaldisorders, around the world. Novartis has bought the treatmentsdeveloped by GlaxoSmithKline, thus acquiring a robust portfolioto help cancer patients. "This operation expands yet furtherNovartis' clinical development programmes for cancer treatment.Currently there are about 340 global clinical studies inprogress and over 25,000 patients recruited across the world.Newly acquired treatments include the ones for melanomas,kidney cancer and haematological disorders (thrombocytopenicpurpura, chronic lymphatic

(AGI) Milan, June 16 - Over 25 new molecules are beingdeveloped to treat 10 neoplasia conditions. In fact, there willbe 22 new drugs to treat patients with cancer or haematologicaldisorders, around the world. Novartis has bought the treatmentsdeveloped by GlaxoSmithKline, thus acquiring a robust portfolioto help cancer patients. "This operation expands yet furtherNovartis' clinical development programmes for cancer treatment.Currently there are about 340 global clinical studies inprogress and over 25,000 patients recruited across the world.Newly acquired treatments include the ones for melanomas,kidney cancer and haematological disorders (thrombocytopenicpurpura, chronic lymphatic leukemia). These new therapeuticoptions complement the ones we have already developed, whichhave become a milestone in the treatment of many types ofcancer," said Luigi Boani, Novartis Oncology General Manager,during a press conference held in Milan on Tuesday. Over tenyears ago, Novartis was the first pharmaceutical company todevelop and launch a global business unit for innovativeoncological medications, to help patients whose needs had notso far been met. Novartis Oncology can count on more than10,000 collaborators across the world, working in the field in85 countries. The Novartis Oncology pipeline includes moleculesin all phases of development, from pre-clinical studies ontumour cell lines and animal models to broad randomised phaseIII clinical studies. The company has a cutting-edge precisiononcology policy.. .

Se avete correzioni, suggerimenti o commenti scrivete a dir@agi.it